Guidelines Developed for Polymyxin Antibiotic Use
Recommendations have been developed for use of polymyxins, focusing on polymyxin B and polymyxin E (colistin); the guidelines were recently published in Pharmacotherapy.
Infectious Disease
AAP: Nasal Spray Vaccine Against Flu Acceptable in 2019 to 2020
Based on current data, AAP Board of Directors says either injection or nasal spray vaccination OK
Short Regimen Noninferior for Rifampin-Resistant Tuberculosis
A short regimen is noninferior to a long regimen for patients with rifampin-resistant tuberculosis that is susceptible to fluoroquinolones and aminoglycosides, according to a new study.
CDC: 228 Measles Cases Already in 2019
Number of cases in the United States so far this year getting close to the total number for all of 2018.
CDC: Flu Season May Have Peaked
t looks like the flu season has peaked in the United States, though there has been a recent rise in the number of cases involving a more severe flu strain.
Mumps Outbreak Reported at Temple University
CDC says more than 2,000 cases of mumps in U.S. last year, 58 cases reported in January of this year
Long-Acting Injectable HIV Regimen Effective in Maintaining Viral Suppression
ViiV Healthcare announced positive 48-week data from the phase 3 ATLAS (N=616) and FLAIR (N=566) studies evaluating a long-acting injectable formulation of cabotegravir + rilpivirine in patients with HIV-1 infection.
Probiotic Sanitation Cuts Antimicrobial Resistance in Hospitals
Impact seen in lower use of antibiotics, costs tied to health care-associated infections
Descovy Non-Inferior to Truvada in Phase 3 HIV PrEP Study
Findings from a phase 3 study evaluating the use of once-daily Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg; Gilead) for HIV pre-exposure prophylaxis (PrEP) demonstrated that the treatment was non-inferior to Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg) for prevention of HIV-1 infection.
FDA to Review Xofluza sNDA for Flu Treatment in Patients at High Risk for Complications
The Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil; Genentech) for the treatment of influenza in patients at high risk of complications.
